Loading patent…
AssigneesHeinrich-Heine-Universitat Dusseldorf, Universität zu Köln
InventorsHelmut Hanenberg, Dieter Niederacher, Kathrin Irmgard Maria Scheckenbach, Rita Schmutzler, Alfons Meindl, Constanze Wiek, Verena Friemann, Marcel Freund
Estimating the term…
The invention discloses in vitro methods and a system for determining a predisposition of a subject for developing a cancer on the basis of analyzing a sample of the subject for an alteration of at least one allele of the RAD51C gene. Further disclosed are in vitro methods for assessing clinical features or a pathological progression of a cancer and for assessing at least one RAD51C gene alteration in a cell. In addition a kit for determining a predisposition of a subject for developing a cancer, and certain uses of oligonucleotides for determining the presence of at least one mono-allelic germ-line mutation of the RAD51C gene.
1-29. (canceled)
An in vitro method for determining a predisposition of a subject for developing a head and neck, breast, or ovarian cancer comprising the step of analyzing in vitro a sample of the subject for an alteration of at least one allele of the RAD51C gene, wherein the alteration of the RAD51C gene is a mono-allelic mutation, which leads to an alteration of the RAD51C gene product with reduced or abolished functionality and indicates a predisposition for developing the cancer.
An in vitro method for assessing a pathological progression of a head and neck, breast, or ovarian cancer of a subject comprising the step of analyzing in vitro a sample of the cancer for a mono-allelic mutation of the RAD51C gene, wherein the presence of at least one mono-allelic mutation in the RAD51C gene leads to an alteration of the RAD51C gene product with reduced or abolished functionality and indicates an increased probability for malignancy and/or invasiveness.
A kit comprising a plurality of oligonucleotides selected from the group consisting of SEQ ID NO:11 to SEQ ID NO:
A method of determining the presence of at least one mono-allelic germ-line mutation of the RAD51C gene in a sample of a subject leading to a RAD51C gene product with reduced or abolished functionality for determining a predisposition of the subject for developing head and neck, breast, or ovarian cancer, which comprises using one or more oligonucleotides selected from the group consisting of SEQ ID NO:
Dependencies are inferred from the claim text.